A case of acute profound thrombocytopenia following abciximab therapy / 대한내과학회지

ABSTRACT

Bleeding and thrombocytopenia are important adverse effects of abciximab. The incidence of abciximab-induced acute profound thrombocytopenia (APT) is low. APT is defined as an abrupt drop in platelet count to <20,000/microL that occurred within 24 hours of administration of an abciximab. This is distinct from all other types of drug-induced thrombocytopenia, which requires a period of drug administration to induce sensitization. If APT occurs and is left untreated, it can cause serious hemorrhage and ischemia that may be fatal. In this case, a 45-year-old man with acute myocardial infarction was administered a bolus intravenous injection of abciximab (0.25 mg/kg), followed by a 12-hour continuous infusion (10 microgram/min) during primary coronary angioplasty. We report a case of APT that was recognized at 2 hours after the initiation of abciximab infusion and was corrected without serious complications.